霉酚酸酯治疗重症肌无力并发原发性中枢神经系统淋巴瘤。

Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.

作者信息

Vernino Steven, Salomao Diva R, Habermann Thomas M, O'Neill Brian P

机构信息

Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9036, USA.

出版信息

Neurology. 2005 Aug 23;65(4):639-41. doi: 10.1212/01.wnl.0000173031.56429.04.

DOI:10.1212/01.wnl.0000173031.56429.04

PMID:16116136

Abstract

Mycophenolate mofetil (MM), an immunosuppressant used after organ transplantation, is also used for treatment of autoimmune myasthenia gravis (MG). A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment. Primary CNS lymphoma regressed on withdrawal of MM. Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with MM may be associated with increased risk of lymphoproliferative disorders.

摘要

霉酚酸酯（MM）是一种用于器官移植后免疫抑制的药物，也用于治疗自身免疫性重症肌无力（MG）。一名全身性MG患者使用MM治疗有效，但在治疗3年后发生了中枢神经系统淋巴瘤。停用MM后原发性中枢神经系统淋巴瘤消退。尽管MM短期副作用极小且疗效明显，但长期用MM治疗MG可能会增加淋巴增殖性疾病的风险。